End Of An Era As Generic Versions Of BMS’s Controversial Blockbuster Revlimid Arrive

Gradual Decline From $12bn Peak Expected

Mar 08 2022

The gradual entry of generics gives BMS extra time to replace Revlimid's lost revenues • Source: Alamy